Phaseline

Companies › Nektar Therapeutics

Nektar Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 2; Immunology, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rezpegaldesleukin (NKTR-358)
Pegylated recombinant human interleukin-2
IL2RA, IL2Phase 3Moderate-to-Severe Atopic Dermatitis; Moderate to Severe Atopic Dermatitis; Type 1 Diabetes MellitusDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06136741Rezpegaldesleukin (NKTR-358)Phase 2Moderate to Severe Atopic DermatitisImmunologyDec 2026
NCT07690371Rezpegaldesleukin (NKTR-358)Phase 3Moderate-to-Severe Atopic DermatitisImmunologyMay 2028
NCT07142252Rezpegaldesleukin (NKTR-358)Phase 2Type 1 Diabetes MellitusMetabolic and endocrineMay 2028
NCT07711418Rezpegaldesleukin (NKTR-358)Phase 3Moderate-to-Severe Atopic DermatitisImmunologyJun 2028

From the company's SEC filings

Cash and short-term investments of $684m on 2026-06-30; operating cash outflow about $243m a year; runway about 34 months at that burn, to Apr 2029; 4 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IL2RA (1) IL2 (1)

Companies with the same targets

Regeneron Pharmaceuticals Synthekine Mural Oncology PolTREG GI Innovation AgonOx CellTrans Innovent Biologics (Suzhou) AstraZeneca Medicenna Therapeutics

Companies built like this

Abeona Therapeutics Doron Therapeutics UnicoCell Biomed Ascendis Pharma Bone Diseases BioXTek

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.